Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Change in Cash (2018 - 2025)

Serina Therapeutics' Change in Cash history spans 8 years, with the latest figure at $2.6 million for Q3 2025.

  • For Q3 2025, Change in Cash rose 189.58% year-over-year to $2.6 million; the TTM value through Sep 2025 reached $5.4 million, up 223.91%, while the annual FY2024 figure was -$3.9 million, 155.69% down from the prior year.
  • Change in Cash for Q3 2025 was $2.6 million at Serina Therapeutics, up from $1.8 million in the prior quarter.
  • Across five years, Change in Cash topped out at $9.4 million in Q1 2023 and bottomed at -$2.9 million in Q3 2024.
  • The 5-year median for Change in Cash is $116000.0 (2021), against an average of $431894.7.
  • The largest YoY upside for Change in Cash was 6997.06% in 2023 against a maximum downside of 568.5% in 2023.
  • A 5-year view of Change in Cash shows it stood at -$147000.0 in 2021, then surged by 221.77% to $179000.0 in 2022, then crashed by 78.77% to $38000.0 in 2023, then skyrocketed by 1050.0% to $437000.0 in 2024, then skyrocketed by 490.16% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Change in Cash are $2.6 million (Q3 2025), $1.8 million (Q2 2025), and $595000.0 (Q1 2025).